CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-31 | LEE KENNETH B JR Director | Option exercise | +15,000 | $1.71 | $26K | 52,118 |
| 2023-01-31 | LEE KENNETH B JR Director | Option exercise · Automatic Stock Option Grant | −15,000 | 0 | ||
| 2022-12-29 | Stonehouse Jon P President & CEO | Gift | −10,000 | 1,008,739 | ||
| 2022-12-29 | Stonehouse Jon P President & CEO | Gift | +5,000 | 10,000 | ||
| 2022-12-29 | Stonehouse Jon P President & CEO | Gift | +5,000 | 10,000 | ||
| 2022-12-19 | Barnes Alane P Chief Legal Officer | Grant or award | +34,000 | 232,770 | ||
| 2022-12-19 | Barnes Alane P Chief Legal Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 | ||
| 2022-12-19 | Thackray Helen M. Chief R&D Officer | Grant or award | +81,000 | 214,275 | ||
| 2022-12-19 | Thackray Helen M. Chief R&D Officer | Grant or award · Emp. Stock Option (Right to Buy) | +238,000 | 238,000 | ||
| 2022-12-19 | Stonehouse Jon P President & CEO | Grant or award | +127,500 | 1,015,230 | ||
| 2022-12-19 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +595,000 | 595,000 | ||
| 2022-12-19 | Jones Michael L Exec. Director, Finance - PAO | Grant or award | +5,900 | 16,653 | ||
| 2022-12-19 | Jones Michael L Exec. Director, Finance - PAO | Grant or award · Emp. Stock Option (Right to Buy) | +8,500 | 8,500 | ||
| 2022-12-19 | Gayer Charles K Chief Commercial Officer | Grant or award | +34,000 | 245,610 | ||
| 2022-12-19 | Gayer Charles K Chief Commercial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 | ||
| 2022-12-19 | Doyle Anthony Chief Financial Officer | Grant or award | +34,000 | 197,966 | ||
| 2022-12-19 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 | ||
| 2022-12-15 | Stonehouse Jon P President & CEO | Sale | −14,100 | $10.90 | $154K | 887,730 |
| 2022-12-15 | Thackray Helen M. Chief R&D Officer | Sale | −3,125 | $10.89 | $34K | 133,275 |
| 2022-12-15 | Doyle Anthony Chief Financial Officer | Sale | −5,700 | $10.90 | $62K | 163,966 |
Page 13 of 18 · 357 trades